Cumberland Pharmaceuticals Reports 14% Revenue Growth In The Second Quarter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Cumberland Pharmaceuticals (CPIX) Tops Q2 EPS by 3c, Revenues Miss
August 14, 2019 4:34 PM EDTCumberland Pharmaceuticals (NASDAQ: CPIX) reported Q2 EPS of $0.10, $0.03 better than the analyst estimate of $0.07. Revenue for the quarter came in at $11.6 million versus the consensus estimate of $12.59 million.
QUARTER HIGHLIGHTS:
Continued a company-wide strategic review of products, partners, and organizationIncreased sales team and national territories to improve support for acute-care key... More